1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 21,400 | 22,800 | 07.02. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.11.25 | BASTIDE: Organic growth of 8.3% in first-quarter 2025-2026: Sustained growth in home healthcare services, up 10.7% / Homecare business up 4.7%, driven by the healthcare institutions business (up 8.5%) | 413 | Actusnews Wire | Caissargues, November 13, 2025 - Groupe Bastide, a leading European provider of home healthcare services, has published its revenue for first-quarter 2025-2026, ending September 30, 2025.
In... ► Artikel lesen | |
| 28.10.25 | BASTIDE: 2025-2026 financial calendar | 956 | Actusnews Wire | Caissargues, October 28, 2025
Events
Dates*
2025-2026 Q1 Revenue
Thursday November 13, 2025
2025-2026 H1 Revenue
Thursday February 12, 2026
2025-2026 H1 Results
Wednesday... ► Artikel lesen | |
| 22.10.25 | BASTIDE: 2024-2025 annual results in line with targets // 2025-26 outlook: Revenue of over EUR 510 million and recurring operating margin around 9%, Leverage of less than 3x and decrease in financial expenses | 748 | Actusnews Wire | Caissargues, October 22, 2025 - Groupe Bastide, a leading European provider of home healthcare services, has announced its 2024-2025 annual results at June 30, 2025. The 2024-2025 annual consolidated... ► Artikel lesen | |
| BASTIDE LE CONFORT MEDICAL Aktie jetzt für 0€ handeln | |||||
| 24.09.25 | BASTIDE: Groupe Bastide completes the sale of Baywater Healthcare to Sapio Group | 692 | Actusnews Wire | Caissargues, September 24, 2025
In line with the timetable set out in its 30 June 2025 communication announcing the agreement to sell Baywater Healthcare, a leading player in the UK respiratory... ► Artikel lesen | |
| 04.09.25 | BASTIDE: 2024-2025 revenue target met // 2024-2025 revenue from continuing operations: EUR 491 million, up 8% ( EUR 561 million, excluding impact of disposals) | 503 | Actusnews Wire | Caissargues, September 4, 2025
Groupe Bastide has published its annual revenue for 2024-2025. In accordance with IFRS 5, reported revenue relates exclusively to continuing operations, and no... ► Artikel lesen | |
| 30.06.25 | BASTIDE: Bastide Groupe Sells Baywater Healthcare To Sapio Group | 658 | Actusnews Wire | Crewe, United Kingdom & Monza, Italy - 30th June 2025
Bastide le Confort Medical SA (hereinafter "Groupe Bastide") today announced that it has agreed to the sale of its subsidiary Baywater Healthcare... ► Artikel lesen | |
| 09.06.25 | BASTIDE: Disposal of CICADUM and MEDSOFT | 546 | Actusnews Wire | Caissargues, June 9, 2025
Bastide Groupe announced today the disposal of its French subsidiaries, Cicadum, 51%-owned, (signing subject to financing condition precedent) and Medsoft, 100%-owned... ► Artikel lesen | |
| 05.06.25 | BASTIDE: Disposal of DORGE and DYNA MEDICAL in Belgium | 533 | Actusnews Wire | Caissargues, June 5, 2025
Bastide Groupe announced today the disposal of its Belgian subsidiaries, Dorge Medic, which specializes in the sale and rental of medical equipment and products for... ► Artikel lesen | |
| 04.06.25 | BASTIDE: Respiratory care therapy: Baywater wins London region tender and consolidates its leading position in the UK | 473 | Actusnews Wire | Caissargues, June 4, 2025
After being chosen one year ago by the National Health Service (NHS) to be the exclusive operator for respiratory care (oxygen therapy) in the East of England region... ► Artikel lesen | |
| 15.05.25 | BASTIDE: Continued strong organic growth in Q3 2024-2025 at +7.7%: Home healthcare services up 10.4% and recovery of Homecare activities confirmed / 2024-2025 targets confirmed | 481 | Actusnews Wire | Caissargues, May 15, 2025
In € millions
2023-2024
published
2023-2024*
Adjusted
2024-2025
published
Change
First-quarter revenue
127.9
122.7
133.8
+9.1%
Second-quarter... ► Artikel lesen | |
| 19.03.25 | BASTIDE: 2024-2025 half-year results / Recurring operating margin at 9.1%, up 80 bps / Operating FCF positive at EUR 9.4 million / Improvement in financial leverage / upward revision of recurring operating margin target to 9.1% | 617 | Actusnews Wire | Caissargues, March 19, 2025 - Groupe Bastide, a leading European provider of home healthcare services, published its 2024-2025 half-year results on December 31, 2024. Groupe Bastide's 2024-2025... ► Artikel lesen | |
| 13.02.25 | BASTIDE: Organic growth of 8.4% in first-half 2024 2025: Home healthcare services up 10.2% and Return to growth in the Homecare business / 2024-2025 targets confirmed | 499 | Actusnews Wire | Caissargues, February 13, 2025
In € millions
2023-2024
published
2023-2024*
Adjusted
2024-2025
published
Change
First-quarter revenue
127.9
122.7
133.8
+9.1%
Second-quarter... ► Artikel lesen |
12 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ANSELL | 18,500 | -2,12 % | Ansell Unveils New Disposable Glove With Extended Acetone Resistance | CANBERA (dpa-AFX) - Ansell Limited (ANSLF), a safety and protection solutions provider, on Monday announced the launch of TouchNTuff 93-800, a new disposable glove designed to provide extended... ► Artikel lesen | |
| AMBEA | 13,040 | -1,06 % | Ambea AB: Ambea further strengthens its offering within child and youth care through an acquisition in Finland | Ambea, through its Finnish business area Validia, has entered into an agreement to acquire Terveystalo Sauma Lastensuojelupalvelut Oy. The acquisition relates to child protection and family care services... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 41,400 | -2,82 % | HV-Termine: Hauptversammlungen bei Adv. Blockchain, Aurubis, Fortec, Schott, Siemens, Healthineers, Stabilus, TUI | Einmal jährlich müssen sich Aufsichtsrat und Vorstand einer Gesellschaft den Aktionären stellen: Die Hauptversammlung ist das höchste Organ einer Aktiengesellschaft und vergleichbarer Unternehmens-Formen.... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 40,640 | +0,40 % | Fresenius Medical Care: Ein Neuanfang nach turbulenten Zeiten? | ||
| FRESENIUS | 49,760 | +1,06 % | JEFFERIES stuft Fresenius SE auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Fresenius mit einem Kursziel von 55 Euro auf "Buy" belassen. Die Bad Homburger seien in Verjüngungskur, und der Markt preise... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 28,740 | +4,89 % | PROCEPT BioRobotics Reports Third Quarter 2025 Financial Results and Issues 2026 Revenue Guidance | SAN JOSE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 39,680 | +3,44 % | BrightSpring Health Services, Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026 | ||
| CARL ZEISS MEDITEC | 27,520 | +0,66 % | BARCLAYS stuft CARL ZEISS MEDITEC AG auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für Carl Zeiss Meditec von 49 auf 32 Euro gesenkt und die Aktien von "Overweight" auf "Equal Weight" abgestuft. Nur... ► Artikel lesen | |
| HEARTFLOW | 27,690 | +6,54 % | Heartflow, Inc.: Heartflow FFRCT Analysis Delivers Prognostic Power and Significant Cost Savings in New Analyses of Over 90,000 Patients with Coronary Artery Disease | Lesion-specific FFRCT predicts individual cardiovascular outcomes and delivers greater-than-modeled cost savings for real-world population in FISH&CHIPS analyses from England's National Health ServiceMOUNTAIN... ► Artikel lesen | |
| GENEDX | 84,35 | +0,32 % | GeneDx to Participate in Upcoming Investor Conferences | GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in upcoming investor conferences:
Stifel... ► Artikel lesen | |
| PRIVIA HEALTH GROUP | 21,990 | +2,23 % | Privia Health Group, Inc.: Privia Health Reports Third Quarter 2025 Financial Results | Very Strong Third Quarter and Year-to-Date Performance Across the BusinessNet Income +94.1% and Adjusted EBITDA +61.6% compared to 3Q'24Implemented Providers +13.1% and Practice Collections +27.1%... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 21,750 | +2,84 % | 6 Analysts Have This To Say About Alignment Healthcare | ||
| GERRESHEIMER | 25,660 | +1,99 % | JEFFERIES stuft GERRESHEIMER AG auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Gerresheimer mit einem Kursziel von 34,10 Euro auf "Buy" belassen. Analyst James Vane-Tempest zählt den Spezialverpackungshersteller... ► Artikel lesen | |
| PROGYNY | 21,960 | +0,18 % | Progyny, Inc. Announces Third Quarter 2025 Results | Reports Revenue of $313.3 Million, Reflecting 9.3% GrowthRaises Full Year Guidance to Reflect Continued Strength in Member EngagementSelling Season Yields Over 80 New Clients, 900,000 New Lives, and... ► Artikel lesen | |
| HIMS & HERS HEALTH | 19,500 | +0,15 % | BREAKING: Hims & Hers verschärft Preisdruck bei Novo Nordisk - Aktie beschleunigt Talfahrt | Der dänische Biopharma-Riese ist erst seit wenigen Wochen mit seinem Appetitzügler Wegovy als Tablette auf dem US-Markt und sieht sich einem massiven Preisdruck ausgesetzt. Das Telehealth-Unternehmen... ► Artikel lesen |
BASTIDE LE CONFORT MEDICAL SA gehört der Branche Gesundheitswesen an. Mit einer aktuellen Kursveränderung von -0,200 (-0,91 %) liegt der Kurs bei 21,750 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BASTIDE LE CONFORT MEDICAL SA finden Sie auf Wallstreet Online.